These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 33837553)
1. Reinduction chemotherapy regimen involved decitabine and cladribine improves the prognosis of patients with relapsed or refractory acute myeloid leukemia: A preliminary study. Hui Y; Li Y; Tong X; Huang L; Mao X; Huang L; Zhang D Int J Cancer; 2021 Apr; ():. PubMed ID: 33837553 [TBL] [Abstract][Full Text] [Related]
2. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582 [TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism. Wang F; Xie M; Chen P; Wang D; Yang M Oxid Med Cell Longev; 2022; 2022():8212286. PubMed ID: 35873796 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia]. Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926 [TBL] [Abstract][Full Text] [Related]
5. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study. Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551 [TBL] [Abstract][Full Text] [Related]
6. [CLAG±DAC regimen in the treatment of refractory/relapsed acute myeloid leukemia]. Hua WX; Yao WQ; Zhou M; Qi JQ; Kang HZ; Wang RJ; Cai CS; Liu YJ; Wu DP; Han Y Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):838-843. PubMed ID: 39414607 [No Abstract] [Full Text] [Related]
7. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. Liu Y; Li Y; Zhang R; Yu Z; Jing Y Front Immunol; 2023; 14():1269163. PubMed ID: 38054008 [TBL] [Abstract][Full Text] [Related]
8. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study. Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488 [TBL] [Abstract][Full Text] [Related]
10. CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Fei X; Zhang W; Gu J; Yang F; Li T; Wang W; Wang J Ann Hematol; 2024 Jan; 103(1):241-249. PubMed ID: 37847380 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial. Zhang C; Gao D; Wang X; Sun X; Yan Y; Yang Y; Zhang J; Yan J Front Oncol; 2023; 13():1142449. PubMed ID: 37664023 [TBL] [Abstract][Full Text] [Related]
12. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene]. Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983 [No Abstract] [Full Text] [Related]
13. Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation. Zhang N; Shao JB; Li H; Yang JW; Chen K; Zhu JS; Jiang H World J Pediatr; 2020 Apr; 16(2):152-158. PubMed ID: 31748985 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review. Mayer K; Hahn-Ast C; Schwab K; Schmidt-Wolf IGH; Brossart P; Glasmacher A; von Lilienfeld-Toal M Eur J Haematol; 2020 Jun; 104(6):538-545. PubMed ID: 32049382 [TBL] [Abstract][Full Text] [Related]
15. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation. Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883 [TBL] [Abstract][Full Text] [Related]
16. Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China. Ding J; Su Y; Ruan Y; Li N; Meng Q; Yang J; Chen L; Liu C Hematology; 2024 Dec; 29(1):2310960. PubMed ID: 38323781 [TBL] [Abstract][Full Text] [Related]
17. Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. Jin M; Hu Y; Wu W; Luo Y; Tan Y; Yu J; Jin A; Yang L; Huang H; Wei G BMC Cancer; 2019 Mar; 19(1):242. PubMed ID: 30885156 [TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662 [TBL] [Abstract][Full Text] [Related]
19. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of two relapsed patients with t(11;19)(q23;p13) acute myeloid leukemia by CLAE chemotherapy sequential with allogeneic hematopoietic stem cell transplantation: Case reports. Tao S; Song L; Deng Y; Chen Y; Gan Y; Li Y; Ding Y; Zhang Z; Ding B; He Z; Wang C; Yu L Oncol Lett; 2021 Mar; 21(3):178. PubMed ID: 33574917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]